Overview
Wegovy® currently has stronger clinical evidence than Mounjaro® for cardiovascular (heart health) benefits. MedExpress prescribes both medications primarily for weight management, but their effect on the cardiovascular system is a key area of ongoing medical research.
Use this article when you want to:
Understand the specific heart health benefits of Wegovy®
Learn the current state of research into Mounjaro®'s heart health benefits
Find out how Wegovy® and Mounjaro® are licensed for cardiovascular use in the UK
Wegovy® and Cardiovascular Risk Reduction
A major clinical trial demonstrated that Wegovy® could significantly protect the heart. The trial showed that Wegovy® could reduce the risk of serious heart problems, such as heart attacks or strokes, by 20% in adults with obesity and existing heart disease.
Because of these trial results, Wegovy® is officially licensed in the UK for use in people with heart disease, to help reduce their cardiovascular risk.
Mounjaro® and Emerging Research
While Mounjaro® has shown excellent results for weight loss and blood sugar control, specific research into its long-term heart health benefits is still emerging.
Researchers expect that Mounjaro® may eventually offer similar cardiovascular protection to Wegovy®, but until the full data from dedicated trials is available, Wegovy® remains the treatment with the most established evidence for heart health specifically.
Choosing the Right Treatment
If you have a history of heart disease, or are concerned about your cardiovascular health, this evidence may be an important factor in your choice between Wegovy® and Mounjaro®.
MedExpress's clinical team can discuss these cardiovascular benefits with you during your consultation, to help ensure your treatment plan aligns with your overall health needs.
Need Further Support?
If you still need help after reviewing the information above, additional assistance is available.